Feedback / Questions
Lynparza (olaparib) - Merck (MSD), AstraZeneca
Lynparza: Acceptance of regulatory submission in US for BRCA mutated ovarian cancer (based on SOLO-3 trial) in H2 2020
(AstraZeneca)
-
Mar 22, 2020 -
Annual Report 2019
sNDA
https://www.astrazeneca.com/content/dam/az/Investor_Relations/annual-report-2019/pdf/AstraZeneca_AR_2019.pdf
Mar 22, 2020
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious